Value of combined baseline serum HBV markers in predicting HBeAg seroconversion in chronic hepatitis B patients treated by nucleos(t)ide analogues
WANG Yang,LIAO Hao,DENG Zhongping,ZHAO Jing,BIAN Dandan,REN Yan,JIANG Yingying,LIU Shuang,CHEN Yu,LU Fengmin,DUAN Zhongping,ZHENG Sujun
DOI: https://doi.org/10.3969/j.issn.1001-5256.2023.05.011
2023-01-01
Abstract:ObjectiveTo investigate the ability of combined baseline serum markers, i.e., HBV DNA, HBV RNA, HBsAg, and HBcrAg, to predict HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B (CHB) treated by nucleos(t)ide analogues. MethodsA retrospective analysis was performed for 83 HBeAg-positive patients selected as subjects from the prospective CHB follow-up cohort established by Difficult & Complicated Liver Diseases and Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University, from June 2007 to July 2008, and the baseline serum levels of HBV DNA, HBV RNA, HBsAg, and HBcrAg were analyzed. The t-test or the Mann-Whitney U test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. The Spearman method was used for correlation analysis. A Cox regression model was established to calculate HBeAg seroconversion prediction score, and the time-dependent receiver operating characteristic curve was used to evaluate the ability of combined markers in predicting HBeAg seroconversion. The Kaplan-Meier method was used to calculate cumulative seroconversion rate in each group, and the Log-rank test was used for comparison between groups. ResultsFor the 83 HBeAg-positive patients, the median follow-up time was 108 months, and 44.58%(37/83) of these patients achieved HBeAg seroconversion. Compared with the non-seroconversion group, the HBeAg seroconversion group had significantly lower baseline serum levels of HBV DNA ［6.23(1.99-9.28) log10IU/mL vs 7.69(2.05-8.96) log10IU/mL, Z=-2.345, P=0019］ and HBV RNA ［4.81(1.40-7.53) log10copies/mL vs 6.22(2.00-8.49) log10copies/mL, Z=-1.702, P=0010］, and there were no significant differences in the levels of HBsAg and HBcrAg between the two groups (P＞0.05). The Cox regression equation constructed based on the above serum markers showed a median score of 0.95(range 0.37-345) for predicting HBeAg seroconversion. In the total population, the combined score was negatively correlated with HBsAg, HBV DNA, HBV RNA, and HBcrAg (r=-0.697, -0.787, -0.990, and -0.819, all P＜0.001). Based on the median prediction score, the patients were divided into high HBeAg seroconversion group and low HBeAg seroconversion group; as for the prediction of HBeAg seroconversion rate at 36, 60, and 84 months, the high HBeAg seroconversion group had a seroconversion rate of 43.90%, 51.20%, and 63.10%, respectively, while the low HBeAg seroconversion group had a seroconversion rate of 9.60%, 17.00%, and 19.8%, respectively, and there was a significant difference between the two groups (χ2=11.6, P＜0.001). ConclusionThe combined prediction score based on baseline serum HBV markers can predict HBeAg seroconversion in CHB patients treated by nucleos(t)ide analogues.